Enterprise Value

312.3M

Cash

62.35M

Avg Qtr Burn

-5.353M

Short % of Float

2.40%

Insider Ownership

1.43%

Institutional Own.

62.30%

Qtr Updated

09/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
REZLIDHIA (Olutasidenib) (FT-2102) Details
Cancer, Acute myeloid leukemia

Approved

Quarterly sales

TAVALISSE® (fostamatinib disodium hexahydrate) Details
Adult Chronic Immune Thrombocytopenia (ITP)

Approved

Quarterly sales

REZLIDHIA (Olutasidenib) (FT-2102) Details
Glioma, Acute myeloid leukemia, Cancer

Approved

Quarterly sales

Phase 3

Data readout

Phase 2

Initiation

R552 Details
Autoimmune disease, Rheumatoid arthritis

Phase 2a

Data readout

R289 Details
Lower-risk myeloid dysplastic syndrome

Phase 1b

Data readout

Failed

Discontinued

Failed

Discontinued